https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43081 Tue 13 Sep 2022 12:19:26 AEST ]]> When do patient reported quality of life indicators become prognostic in breast cancer? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32263 Mon 23 Sep 2019 10:48:43 AEST ]]>